Literature DB >> 15754428

Proapoptotic and pronecrosis effect of different truncated hepatitis C virus core proteins.

Xue-bing Yan1, Zhi Chen, Dong-hui Luo, Xiao-yan Xu, Wei Wu, Lin-fu Zhou.   

Abstract

OBJECTIVE: To study the roles of different truncated hepatitis C virus (HCV) core proteins (CORE) in the pathogenesis of HCV persistent infection and hepatocellular carcinoma (HCC) and to assess intracellular localization in transiently transfected cells.
METHODS: Seven truncated GFP (green fluorescent protein)-CORE fusion protein expression plasmids were constructed, which contained HCV CORE sequences derived from tumor tissues (BT) and non-tumor tissues (BNT) from one patient infected with HCV. Amino acid (aa) lengths were BT: 1-172 aa, 1-126 aa, 1-58 aa, 59-126 aa, 127-172 aa; BNT: 1-172 aa and C191: 1-172 aa respectively. Subcellular localization of CORE-GFP was analyzed by con-focal laser scanning microscope. Apoptosis and necrosis were quantified by flow cytometry.
RESULTS: Different truncated CORE-GFP localized mainly in the cytoplasm, but nuclear staining was also observed. HCV CORE could induce apoptosis and necrosis, and different truncated COREs could induce cell apoptosis and necrosis at different levels. Among the same length 1-172 aa of BT, BNT and C191, the cell apoptosis and necrosis percentage of BT is highest, and C191 is the lowest (BT>BNT>C191). To the different fragment COREs of BT, N-terminal of CORE induced apoptosis and necrosis higher, compared with that of C-terminal (1-172 aa>1-126 aa>1-58 aa>127-172 aa>59-126 aa).
CONCLUSION: These results suggest HCV CORE could induce apoptosis and necrosis of cells, which might play an important role in the pathogenesis of HCV persistent infection and HCC and the different CORE domains of different HCV quasi-species might have some difference in their pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754428      PMCID: PMC1389739          DOI: 10.1631/jzus.2005.B0295

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  15 in total

1.  Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression.

Authors:  Motoyuki Otsuka; Naoya Kato; Hiroyoshi Taniguchi; Hideo Yoshida; Tadashi Goto; Yasushi Shiratori; Masao Omata
Journal:  Virology       Date:  2002-04-25       Impact factor: 3.616

2.  Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein.

Authors:  N Delhem; A Sabile; R Gajardo; P Podevin; A Abadie; M A Blaton; D Kremsdorf; L Beretta; C Brechot
Journal:  Oncogene       Date:  2001-09-13       Impact factor: 9.867

Review 3.  Hepatitis C virus core protein: intriguing properties and functional relevance.

Authors:  R B Ray; R Ray
Journal:  FEMS Microbiol Lett       Date:  2001-08-21       Impact factor: 2.742

4.  Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation.

Authors:  D Y Jin; H L Wang; Y Zhou; A C Chun; K V Kibler; Y D Hou; H Kung; K T Jeang
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

5.  Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation.

Authors:  Stefano Realdon; Martina Gerotto; Francesca Dal Pero; Oriano Marin; Anna Granato; Giuseppe Basso; Maurizio Muraca; Alfredo Alberti
Journal:  J Hepatol       Date:  2004-01       Impact factor: 25.083

Review 6.  Apoptosis in hepatitis C.

Authors:  J Kountouras; C Zavos; D Chatzopoulos
Journal:  J Viral Hepat       Date:  2003-09       Impact factor: 3.728

7.  Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression.

Authors:  Takayuki Yamanaka; Tatsuhiko Kodama; Takefumi Doi
Journal:  Biochem Biophys Res Commun       Date:  2002-06-14       Impact factor: 3.575

8.  Hepatitis C virus f protein is a short-lived protein associated with the endoplasmic reticulum.

Authors:  Zhenming Xu; Jinah Choi; Wen Lu; Jing-hsiung Ou
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.

Authors:  C François; G Duverlie; D Rebouillat; H Khorsi; S Castelain; H E Blum; A Gatignol; C Wychowski; D Moradpour; E F Meurs
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

10.  Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein.

Authors:  A Naganuma; A Nozaki; T Tanaka; K Sugiyama; H Takagi; M Mori; K Shimotohno; N Kato
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

View more
  4 in total

1.  Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs.

Authors:  Saba Khaliq; Shah Jahan; Bushra Ijaz; Waqar Ahmad; Sultan Asad; Asim Pervaiz; Baila Samreen; Mahwish Khan; Sajida Hassan
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

2.  Hepatitis C viral heterogeneity based on core gene and an attempt to design small interfering RNA against strains resistant to interferon in rawalpindi, pakistan.

Authors:  Sobia Kanwal; Tariq Mahmood
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

3.  Associations among Genotype 1b Hepatitis C Virus Core Protein, Protein Kinase R, and Signal Transducer and Activator of Transcription 3.

Authors:  Xue Bing Yan; Zhi Chen; Christian Brechot
Journal:  Hepat Mon       Date:  2010-12-01       Impact factor: 0.660

4.  Charge neutralization as the major factor for the assembly of nucleocapsid-like particles from C-terminal truncated hepatitis C virus core protein.

Authors:  Theo Luiz Ferraz de Souza; Sheila Maria Barbosa de Lima; Vanessa L de Azevedo Braga; David S Peabody; Davis Fernandes Ferreira; M Lucia Bianconi; Andre Marco de Oliveira Gomes; Jerson Lima Silva; Andréa Cheble de Oliveira
Journal:  PeerJ       Date:  2016-11-09       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.